A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Trial Profile

A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 06 Dec 2016 Results of long-term follow-up (five-year) resented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Apr 2016 Status changed from discontinued to completed.
    • 08 Dec 2015 Results of updated long-term follow-up were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top